Formulação de dietas de custo mínimo da matéria seca para bovinos de corte em planilha eletrônica.

ABSTRACT: The diet is one of the main costs animal production in feedlots. In addition, diet composition is one of the main determinants of the animal's performance. Therefore, adequate diet formulation is crucial for the success of the feedlot. This publication describes the fundamentals of diet formulation through the criteria of least cost of dry matter and teaches how to implement it in a electronic spreadsheet for diet formulation. The aim is to allow spreadsheet users to easily evaluate and formulate diets for bovines.bitstream/CPAC-2009/25873/1/comtec_98.pd

Mattos et al Primary coronary intervention for AMI in diabetics Arq Bras Cardiol 2001; 77: 556-61. One-Year Follow-Up After Primary Coronary Intervention for Acute Myocardial Infarction in Diabetic Patients. A Substudy of the STENT PAMI Trial Original Art

Objective -This analysis was undertaken to determine the composite incidence of cumulative adverse events (death, reinfarction, disabling stroke, and target vessel revascularization) at the end of the first year after acute myocardial infarction, in diabetic patients who underwent coronary stenting or primary coronary balloon angioplasty. The STENT PAMI trial was a multinational randomized trial designed to compare the 6-month and 1-year clinical and angiographic outcomes of primary coronary balloon angioplasty (PTCA) and the routine implantation of coronary stents for acute myocardial infarction (AMI) with less than 12 hours of symptom onset 1,2 . From previous consecutive series of elective coronary stenting, the clinical presence of diabetes mellitus (DM) remains as an independent predictor of the occurrence of major adverse events at late follow-up 3-6 . In these series of non-AMI patients, diabetic patients who underwent coronary stent implantation showed a significantly higher rate of major coronary events, including death and new target vessel revascularization rates (TVR) at 6 months, and these were even higher in patients with insulin dependent diabetes 3-6 . However, the possible benefits from routine stenting in diabetic patients who undergo percutaneous coronary interventions in the first hours of AMI onset are still not clear. Little data exist that report the 1-year clinical and 6-month angiographic outcomes between of primary coronary stenting or balloon PTCA in diabetic patients with AMI 7-9 . The objectives of this study were to compare the 1-year clinical and 6-month angiographic outcomes of diabetic and nondiabetic patients randomized to routine coronary stenting or PTCA in the first 12 hours of AMI onset, who were included in the STENT PAMI randomized trial. Methods - Methods Patients were considered for the trial if they were >18 years of age, had symptoms of myocardial infarction less than 12 hours prior to signing an informed consent and had either ST-T segment elevation >1mm (in 2 or more contiguous leads) or new left bundle-branch block. Clinical exclusion criteria included prior administration of thrombolytics fo

Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry

Aims: Dilated cardiomyopathy (DCM) is a complex disease where genetics interplay with extrinsic factors. This study aims to compare the phenotype, management, and outcome of familial DCM (FDCM) and non-familial (sporadic) DCM (SDCM) across Europe. Methods and results: Patients with DCM that were enrolled in the prospective ESC EORP Cardiomyopathy & Myocarditis Registry were included. Baseline characteristics, genetic testing, genetic yield, and outcome were analysed comparing FDCM and SDCM; 1260 adult patients were studied (238 FDCM, 707 SDCM, and 315 not disclosed). Patients with FDCM were younger (P\ua0<\ua00.01), had less severe disease phenotype at presentation (P\ua0<\ua00.02), more favourable baseline cardiovascular risk profiles (P\ua0 64\ua00.007), and less medication use (P\ua0 64\ua00.042). Outcome at 1\ua0year was similar and predicted by NYHA class (HR 0.45; 95% CI [0.25\u20130.81]) and LVEF per % decrease (HR 1.05; 95% CI [1.02\u20131.08]. Throughout Europe, patients with FDCM received more genetic testing (47% vs. 8%, P\ua0<\ua00.01) and had higher genetic yield (55% vs. 22%, P\ua0<\ua00.01). Conclusions: We observed that FDCM and SDCM have significant differences at baseline but similar short-term prognosis. Whether modification of associated cardiovascular risk factors provide opportunities for treatment remains to be investigated. Our results also show a prevalent role of genetics in FDCM and a non-marginal yield in SDCM although genetic testing is largely neglected in SDCM. Limited genetic testing and heterogeneity in panels provides a scaffold for improvement of guideline adherence